TELA Bio, Inc. (NASDAQ:TELA – Get Free Report) CEO Antony Koblish bought 88,888 shares of the business’s stock in a transaction dated Thursday, October 24th. The stock was acquired at an average cost of $2.25 per share, for a total transaction of $199,998.00. Following the purchase, the chief executive officer now owns 458,897 shares in the company, valued at approximately $1,032,518.25. This trade represents a 0.00 % increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink.
TELA Bio Stock Down 2.6 %
Shares of NASDAQ:TELA traded down $0.07 during midday trading on Thursday, reaching $2.58. The company had a trading volume of 540,218 shares, compared to its average volume of 184,861. The stock has a market capitalization of $63.75 million, a P/E ratio of -1.50 and a beta of 0.99. The stock’s fifty day moving average price is $2.68 and its 200-day moving average price is $4.16. The company has a debt-to-equity ratio of 14.22, a current ratio of 3.41 and a quick ratio of 2.52. TELA Bio, Inc. has a one year low of $2.30 and a one year high of $7.84.
TELA Bio (NASDAQ:TELA – Get Free Report) last announced its quarterly earnings data on Monday, August 12th. The company reported ($0.51) earnings per share for the quarter, missing the consensus estimate of ($0.45) by ($0.06). The company had revenue of $16.09 million for the quarter, compared to analyst estimates of $19.00 million. TELA Bio had a negative return on equity of 252.57% and a negative net margin of 65.04%. During the same period in the prior year, the business earned ($0.46) earnings per share. Equities research analysts expect that TELA Bio, Inc. will post -1.39 earnings per share for the current fiscal year.
Institutional Trading of TELA Bio
Analysts Set New Price Targets
TELA has been the subject of several recent research reports. Piper Sandler lowered their price target on TELA Bio from $10.00 to $8.00 and set an “overweight” rating for the company in a report on Tuesday, August 13th. Canaccord Genuity Group reiterated a “buy” rating and set a $12.00 target price on shares of TELA Bio in a report on Friday, October 4th. Lake Street Capital decreased their price target on TELA Bio from $14.00 to $8.00 and set a “buy” rating for the company in a report on Tuesday, August 13th. Finally, JMP Securities dropped their price objective on shares of TELA Bio from $15.00 to $12.00 and set a “market outperform” rating on the stock in a research note on Tuesday, August 13th.
Read Our Latest Stock Analysis on TELA
About TELA Bio
TELA Bio, Inc, a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs.
Featured Articles
- Five stocks we like better than TELA Bio
- Buy P&G Now, Before It Sets A New All-Time High
- Why Meta’s Pre-Earnings Dip Could Be A Golden Entry Opportunity
- Trading Stocks: RSI and Why it’s Useful
- Spirit Airlines Stock Nearly Doubled: Are Clear Skies Ahead?
- ESG Stocks, What Investors Should Know
- Tesla Stock: Buy the Dips, Sell the Rips
Receive News & Ratings for TELA Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TELA Bio and related companies with MarketBeat.com's FREE daily email newsletter.